Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model

Journal of Investigative Dermatology

Volumn 120, Issue 3, 2003, Pages 476-482

  Kunstfeld, Rainer ^a   Wickenhauser, Georg ^a   Michaelis, Uwe ^b   Teifel, Michael ^b   Umek, Wolfgang ^c   Naujoks, Kurt ^b   Wolff, Klaus ^a,d   Petzelbauer, Peter ^a,d  

^a Universitatsklinik fur Dermatologie   (Austria)

^b Munich Biotech AG   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Antiangiogenesis; Cationic liposomes; Melanoma; Paclitaxel; SCID mouse

Indexed keywords

CREMOPHOR; LIPOSOME; PACLITAXEL;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DERMIS; DRUG EFFECT; DRUG SOLUBILITY; DRUG TARGETING; DRUG TRANSPORT; ENCAPSULATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MELANOMA; MITOSIS; MITOSIS INDEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; VESSEL;

EID: 0037335129     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2003.12057.x     Document Type: Article

References (36)

1. Arap W, Pasqualini R, Ruoslahti E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377-380, 1998
2. Belotti D, Vergani V, Drudis T, et al: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843-1849, 1996
3. Brien SE, Zagzag D, Brem S: Rapid in situ cellular kinetics of intracerebral tumor angiogenesis using a monoclonal antibody to bromodeoxyuridine. Neurosurgery 25:715-719, 1989
4. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886, 2000
5. Cabanes A, Briggs KE, Gokhale PC, Treat JA, Rahman A: Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol 12:1035-1040, 1998
6. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 407:249-257, 2000
7. Chang AY, Boros L, Asbury R, Hui L, Rubins J: Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer. Semin Oncol 24:S17-S17, 1997
8. Ellerby HM, Arap W, Ellerby LM, et al: Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5:1032-1038, 1999
9. Featherstone J, Griffiths S: From the analyst's coach: drugs that target angiogenesis. Nature Rev Drug Discovery 1:413-414, 2002
10. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186, 1971
11. Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, Adams GL: Phase III comparison of high-dose paclitaxel - cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern cooperative oncology group study e1393. J Clin Oncol 19:1088-1095, 2001
12. Gasparini G: Metronomic scheduling. The future of chemotherapy? Lancet Oncol 2:733-740, 2001
13. Gröger M, Fischer GF, Wolff K, Petzelbauer P: Immune complexes from vasculitis patients bind to endothelial Fc receptors independent of the allelic polymorphism of FcgammaR11a. J Invest Dermatol 113:56-60, 1999
14. Harigai T, Kondo M, Isozaki M, Kasukawa H, Hagiwara H, Uchiyama H, Kimura J: Preferential binding of polyethylene glycol-coated liposomes containing a novel cationic lipid, TRX-20, to human subendothelial cells via chondroitin sulfate. Pharm Res 18:1284-1290, 2001
15. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363-1380, 1997
16. Hu Z, Garen A: Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci USA 98:12180-12185, 2001
17. Klement G, Baruchel S, Rak J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24, 2000
18. Kunstfeld R, Lechleitner S, Gröger M, Wolff K, Petzelbauer P: HECA-452 + T cells migrate through superficial vascular plexus but not through deep vascular plexus endothelium. J Invest Dermatol 108:343-348, 1997
19. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT: Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 14:31-36, 1999
20. Ling YH, Zhong Y, Perez SR: Disruption of cell adhesion and caspase-mediated proteolysis of β-and γ-catenins and APC protein in paclitaxel-induced apoptosis. Mol Pharmacol 59:593-603, 2001
21. Liu Y, Mounkes LC, Liggitt HD, Brown CS, Solodin I, Heath TD, Debs RJ: Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol 15:167-173, 1997
22. McLean JW, Fox EA, Baluk P, et al: Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. Am J Physiol 273:H387-H404, 1997
23. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
24. Nilsson F, Kosmehl H, Zardi L, Neri D: Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61:711-716, 2001
25. Norman JT, Clark IM, Garcia PL: Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 58:2351-2366, 2000
26. Oku N, Tokudome Y, Asai T, Tsukada H: Evaluation of drug targeting strategies and liposomal trafficking. Curr Pharm Des 6:1669-1691, 2000
27. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1998
28. Petzelbauer P, Bender JR, Wilson J, Pober JS: Heterogeneity of dermal microvascular endothelial cell antigen expression and cytokine responsiveness in situ and in cell culture. J Immunol 151:5062-5072, 1993
29. Petzelbauer P, Gröger M, Kunstfeld R, Petzelbauer E, Wolff K: Human delayed-type hypersensitivity reaction in a SCID mouse engrafted with human T cells and autologous skin. J Invest Dermatol 107:576-581, 1996
30. Ramesh R, Saeki T, Templeton NS, et al: Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther 3:337-350, 2001
31. Rathmann J, Leopold KA, Rigas JR: Daily paclitaxel and thoracic radiation therapy for non-small cell lung cancer: preliminary results. Semin Radiat Oncol 9:130-135, 1999
32. Sharma D, Chelvi TP, Kaur J, De Chakravorty KTK, Maitra A, Ralhan R: Novel TaxolR formulation: polyvinylpyrrolidone nanoparticle-encapsulated TaxolR for drug delivery in cancer therapy. Oncol Res 8:281-286, 1996
33. Sugano M, Egilmez NK, Yokota SJ, Chen FA, Harding J, Huang SK, Bankert RB: Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 60:6942-6949, 2000
34. Tajima R, Kawaguchi N, Horino Y. et al: Hypoxic enhancement of type IV collagen secretion accelerates adipose conversion of 3T3-L1 fibroblasts. Biochem Biophys Acta Mol Cell Res 1540:179-187, 2001
35. Thurston G, McLean JW, Rizen M, et al: Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 101:1401-1413, 1998
36. Zhou R, Mazurchuk R, Straubinger RM: Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res 62:2561-2566, 2002